Literature DB >> 28856475

Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study.

Garland Castaneda1, Benny Liu2, Sharon Torres2, Taft Bhuket2, Robert J Wong3.   

Abstract

BACKGROUND: While ulcerative colitis (UC) is well studied in Caucasian populations, less data are available on UC patients of racial/ethnic minorities, including variations in disease severity at presentation. AIM: To evaluate race/ethnicity-specific disparities in UC disease presentation among an ethnically diverse underserved population.
METHODS: We performed a cross-sectional study of all consecutive UC adults among a large ethnically diverse safety-net hospital from July 2014 to May 2016 to compare race/ethnicity-specific disparities in severity of disease at presentation. Severity was evaluated using the clinician-based simple clinical colitis activity index (SCCAI) and the Mayo score at time of presentation. Multivariate ordered logistic regression models were used to evaluate associations with SCCAI and Mayo scores.
RESULTS: Among 98 UC patients (56.1% male, mean age 40.1 (SD 14.2), 32.0% were African-American, 26.7% Hispanic, 16.0% Asian, and 20.0% Caucasian. Mean Mayo score was 6.6 and mean SCCAI score was 6.5. When stratified by race/ethnicity, SCCAI scores were significantly higher in non-Caucasians compared to Caucasians (7.0 vs 4.6, p = 0.03) and in Asians compared to Caucasians (8.0 vs 4.6, p = 0.02). There was a trend toward higher mean SCCAI in Hispanics compared to Caucasians (6.9 vs 4.6, p = 0.07). Mayo scores at presentation demonstrated similar trends. On multivariate logistic regression, Asians (OR 5.26, 95% CI 1.24-22.42) and Hispanics (OR 3.74; 95% CI 1.02-13.66) had more severe disease at presentation than Caucasians based on SCCAI.
CONCLUSIONS: Among a diverse underserved cohort of UC patients, racial/ethnic minority patients with UC, specifically Asians and Hispanics, had more severe disease at presentation compared to Caucasians. The differences may reflect disparities in timely access to specialty care and treatment and deserves greater attention and research.

Entities:  

Keywords:  Disparities; Inflammatory bowel disease; Mayo score; Safety-net

Mesh:

Year:  2017        PMID: 28856475     DOI: 10.1007/s10620-017-4733-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

Review 1.  Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review.

Authors:  Jason K Hou; Hashem El-Serag; Selvi Thirumurthi
Journal:  Am J Gastroenterol       Date:  2009-05-26       Impact factor: 10.864

2.  Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital.

Authors:  M Anthony Sofia; David T Rubin; Ningqi Hou; Joel Pekow
Journal:  Dig Dis Sci       Date:  2014-04-22       Impact factor: 3.199

3.  Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings.

Authors:  Lisa J Herrinton; Liyan Liu; Jennifer Elston Lafata; James E Allison; Susan E Andrade; Eli J Korner; K Arnold Chan; Richard Platt; Deborah Hiatt; Siobhán O'Connor
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

Review 4.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.

Authors:  Brian Bressler; John K Marshall; Charles N Bernstein; Alain Bitton; Jennifer Jones; Grigorios I Leontiadis; Remo Panaccione; A Hillary Steinhart; Francis Tse; Brian Feagan
Journal:  Gastroenterology       Date:  2015-03-04       Impact factor: 22.682

5.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

7.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

8.  Race and inflammatory bowel disease in an urban healthcare system.

Authors:  Justin L Sewell; John M Inadomi; Hal F Yee
Journal:  Dig Dis Sci       Date:  2010-10-09       Impact factor: 3.199

9.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

10.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Authors:  Isabelle Cleynen; Gabrielle Boucher; Luke Jostins; L Philip Schumm; Sebastian Zeissig; Tariq Ahmad; Vibeke Andersen; Jane M Andrews; Vito Annese; Stephan Brand; Steven R Brant; Judy H Cho; Mark J Daly; Marla Dubinsky; Richard H Duerr; Lynnette R Ferguson; Andre Franke; Richard B Gearry; Philippe Goyette; Hakon Hakonarson; Jonas Halfvarson; Johannes R Hov; Hailang Huang; Nicholas A Kennedy; Limas Kupcinskas; Ian C Lawrance; James C Lee; Jack Satsangi; Stephan Schreiber; Emilie Théâtre; Andrea E van der Meulen-de Jong; Rinse K Weersma; David C Wilson; Miles Parkes; Severine Vermeire; John D Rioux; John Mansfield; Mark S Silverberg; Graham Radford-Smith; Dermot P B McGovern; Jeffrey C Barrett; Charlie W Lees
Journal:  Lancet       Date:  2015-10-18       Impact factor: 202.731

View more
  4 in total

Review 1.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

2.  Combination of vedolizumab and immunomodulators in ulcerative colitis.

Authors:  P Pinton
Journal:  J Gastroenterol Hepatol       Date:  2021-09-22       Impact factor: 4.369

3.  Gut microbiota diversity across ethnicities in the United States.

Authors:  Andrew W Brooks; Sambhawa Priya; Ran Blekhman; Seth R Bordenstein
Journal:  PLoS Biol       Date:  2018-12-04       Impact factor: 8.029

4.  Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey.

Authors:  Toshifumi Hibi; Toyomi Ishibashi; Yuka Ikenoue; Ryoichi Yoshihara; Akiko Nihei; Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2020-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.